US 12,240,839 B2
Cyclobutyl dihydroquinoline sulfonamide compounds
Benjamin C Milgram, Cambridge, MA (US); Isaac E Marx, Arlington, MA (US); Haoxuan Wang, Somerville, MA (US); and Alan H Cherney, Somerville, MA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 17/633,151
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Jun. 10, 2021, PCT No. PCT/US2021/036896
§ 371(c)(1), (2) Date Feb. 4, 2022,
PCT Pub. No. WO2021/252820, PCT Pub. Date Dec. 16, 2021.
Claims priority of provisional application 63/037,001, filed on Jun. 10, 2020.
Prior Publication US 2022/0306604 A1, Sep. 29, 2022
Int. Cl. C07D 413/12 (2006.01); A61P 25/04 (2006.01); C07D 215/36 (2006.01); C07D 401/12 (2006.01)
CPC C07D 413/12 (2013.01) [A61P 25/04 (2018.01); C07D 215/36 (2013.01); C07D 401/12 (2013.01)] 14 Claims
 
1. A compound of Formula (Ia), or an enantiomer, diastereoisomer, atropisomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein: R1a is fluoro, chloro, methyl, —O—CF3, or CF3;
R2 is H, halo, C1-6alk, or C1-6haloalk;
R3 is C1-6alk, C1-6haloalk, —O—C1-6alk, or —CN;
R4 is a 5- to 6-membered heteroaryl;
each of R6 and R7 is hydrogen; and
each of R5a; R5b; R5c; R5d; and R5e is independently hydrogen or halo.